Sophia Antipolis, France

MEDIAN will demonstrate its Lesion Management Solutions (LMS) and discuss the results of its abstract at Booth #4125, Hall B.

MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, today announced its participation in the 2014 ASCO annual conference, to be held next May 30 – June 3, in Chicago, IL, USA (exhibition dates: May 31-June 2).

During ASCO, the world’s premier oncology conference, representatives from MEDIAN will be present at Booth #4125, Hall B to give demonstrations of their Lesion Management Solutions software and to discuss their abstract, ‘Volume-based Response Evaluations with Consensual Lesion Selection Using Cloud Solutions in Clinical Trials’. The use of lesion volume is considered as a promising alternative to RECIST (Response Evaluation Criteria in Solid Tumors) to make tumor measurements more accurate, consistent, and for earlier detection of changes. The pilot study conducted by MEDIAN aimed at evaluating the effects of target (TL) and new lesions (NL) selection on volume-based response (VBR) assessments. The study was carried out on lung cancer patients CT scans. Images were analyzed according to RECIST and VBR criteria by two oncologists (Japan and Scotland) and one radiologist (France) by using cloud solutions (MEDIAN Technologies). This study provides additional evidence about the benefit of using VBR over RECIST. The use of cloud solutions showed to be an interesting and feasible strategy for standardizing response evaluations and reducing variability in multi-center clinical trials. This type of initiative is of great importance for increasing consistency in the production of trial results.

Download ASCO2014_Participation.pdf